ClinicalTrials.gg
Active, not recruitingNCT06516952Updated May 28, 2026

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

A Phase 3 interventional study of Povorcitinib and Placebo in Prurigo Nodularis, sponsored by Incyte Corporation. Active, not recruiting at 120 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Enrollment
4th of 21
349 · median 140
Started
2024
with 6 others
Phase 3
10 of 23
1 open now
Registered
17th of 23
by date
Lead sponsor
6 of 23
Incyte Corporation

Among the 23 studies in Prurigo with a site in United States, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2024, is one of 10 in phase 3, and was the 17th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

Keywords

  • Prurigo nodularis
  • PN
  • INCB054707
  • chronic pruritus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants 18 to 75 years of age.
  • Clinical diagnosis of PN for at least 3 months prior to Screening visit.
  • Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day 1/Baseline.
  • Total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at Screening and Day 1/Baseline.
  • Documented history of treatment failure, demonstrated intolerance, or to a previous PN treatment.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Chronic pruritus due to a condition other than PN or neuropathic and psychogenic pruritus.
  • Diagnosis of PN secondary to medications.
  • Active AD lesions (signs and symptoms other than dry skin) within 3 months prior to Screening visit.
  • Women who are pregnant (or are considering pregnancy) or breastfeeding.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; .
  • Evidence of infection with TB, , or .
  • History of failure to any topical or systemic JAK or TYK2 inhibitor as treatment of PN or any inflammatory disease.
  • Laboratory values outside of the protocol-defined ranges.

Other protocol-defined Inclusion/Exclusion Criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
349 participants (actual)

Study arms

  • Experimental
    Povorcitinib Dose 1

    Povorcitinib at the protocol-defined dose.

    Drug: Povorcitinib

  • Experimental
    Povorcitinib Dose 2

    Povorcitinib at the protocol-defined dose.

    Drug: Povorcitinib

  • Placebo comparator
    Placebo

    Placebo at the protocol-defined dose.

    Drug: Placebo

Interventions

  • Oral Tablet

    Also known as: INCB054707

  • DrugPlacebo

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24

    Defined as proportion of participants achieving a ≥ 4-point improvement \[reduction\] in Itch NRS score from baseline (Itch NRS4) and an IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline (IGA-CPG-S-TS).

    Time frame: Week 24

Secondary outcomes

  1. Proportion of participants achieving Itch NRS4 at Week 24

    Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline.

    Time frame: Week 24

  2. Proportion of participants achieving IGA-CPG-S-TS at Week 24

    Defined as percentage of participants that achieve IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline.

    Time frame: Week 24

  3. Proportion of participants achieving Itch NRS4 at Week 4

    Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score from baseline.

    Time frame: Week 4

  4. Time to Itch NRS4

    Defined as time taken for the participant to achieve a ≥4 improvement in Itch NRS score from baseline.

    Time frame: Up to 52 weeks

  5. Change from baseline in Itch NRS score at each postbaseline visit

    Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable".

    Time frame: Up to 52 weeks

  6. Percent change from baseline in NRS score at each postbaseline visit

    Itch will be measured using an NRS used to indicate the intensity of the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where "0" represents "no itching" and "10" represents "worst itching imaginable".

    Time frame: Up to 52 weeks

  7. Proportion of participants achieving Itch NRS4 at each postbaseline visit

    Defined as percentage of participants that achieve a ≥ 4-point improvement in Itch NRS score from baseline.

    Time frame: Up to 52 weeks

  8. Proportion of participants achieving IGA-CPG-S-TS at each postbaseline visit

    Defined as percentage of participants that achieve an IGA-CPG-S score of 0 or 1 with a ≥ 2 grade improvement from baseline.

    Time frame: Up to 52 weeks

  9. Proportion of participants achieving Investigator's Global Assessment - Chronic Prurigo Activity (IGA-CPG-A) at each postbaseline visit

    Defined as percentage of participants that achieve an IGA-CPG-A score of 0 or 1 with a ≥ 2 grade improvement (reduction) from baseline.

    Time frame: Up to 52 weeks

  10. Proportion of participants achieving ≥ 75% healed lesions in Prurigo Activity Score (PAS) at each postbaseline visit

    The modified PAS will be used in this study as defined by the protocol.

    Time frame: Up to 52 weeks

  11. Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at each postbaseline visit

    Defined as percentage of participants that achieve a ≥ 4-point improvement (reduction) in Itch NRS score and IGA-CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline.

    Time frame: Up to 52 weeks

  12. Change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.

    The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days.

    Time frame: Up to 52 weeks

  13. Percent change from baseline in Dermatology Life Quality Index (DLQI) score at each postbaseline visit.

    The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days.

    Time frame: Up to 52 weeks

  14. Proportion of participants with at least a 4-point decrease in DLQI score from baseline at each postbaseline visit for participants with DLQI score ≥ 4 at baseline

    Defined as percentage of participants with at least a 4-point decrease in DLQI score from baseline at each postbaseline visit for participants with DLQI score ≥ 4 at baseline.

    Time frame: Up to 52 weeks

  15. Change from baseline in Skin Pain NRS score at each postbaseline visit

    Skin Pain NRS is an 11-point scale (0 to10) where 0 is "no pain" and 10 is the "worst pain imaginable".

    Time frame: Up to 52 weeks

  16. Percent change from baseline in Skin Pain NRS score at each postbaseline visit

    Skin Pain NRS is an 11-point scale (0 to10) where 0 is "no pain" and 10 is the "worst pain imaginable".

    Time frame: Up to 52 weeks

  17. Change from baseline in the Hospital Anxiety and Depression Scale (HADS) score at each postbasline visit

    HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3).

    Time frame: Up to 52 weeks

  18. Percent change from baseline in the HADS score at each postbaseline visit

    HADS is a 14-item questionnaire that assesses the levels of anxiety and depression that a participant is currently experiencing. There are 7 questions each for measuring anxiety and for measuring depression, with 4 possible responses to each question (responses are scored as 0, 1, 2, or 3).

    Time frame: Up to 52 weeks

  19. Change from baseline in EQ-5D-5L score at each postbaseline visit

    The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome.

    Time frame: Up to 52 weeks

  20. Percent change from baseline in EQ-5D-5L score at each postbaseline visit

    The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome.

    Time frame: Up to 52 weeks

  21. Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score at each postbaseline visit

    The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days.

    Time frame: Up to 52 weeks

  22. Percent change in FACIT-F score at each postbaseline visit

    The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days.

    Time frame: Up to 52 weeks

  23. Proportion of participants with at least a ≥ 4-point increase in FACIT-F score at each postbaseline visit for participants with FACIT-F score ≤ 48 at baseline

    The FACIT-F is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days.

    Time frame: Up to 52 weeks

  24. Number of Participants with Treatment Emergent Adverse Events (TEAE)

    Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to 52 weeks

07

Study locations

120 sites

Showing the first 100 of 120 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 24, 2024
StartActual
Oct 10, 2024
Primary completionEst.
Oct 19, 2026
CompletionEst.
May 3, 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06516952
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Oct 10, 2024
Primary completion
Oct 19, 2026 (estimated)
Completion
May 3, 2027 (estimated)
Last update
May 28, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion